Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

853 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Long-term effects of interleukin-17A inhibition with secukinumab in active ankylosing spondylitis: 3-year efficacy and safety results from an extension of the Phase 3 MEASURE 1 trial.
Baraliakos X, Kivitz AJ, Deodhar AA, Braun J, Wei JC, Delicha EM, Talloczy Z, Porter B; MEASURE 1 Study Group. Baraliakos X, et al. Among authors: porter b. Clin Exp Rheumatol. 2018 Jan-Feb;36(1):50-55. Epub 2017 May 15. Clin Exp Rheumatol. 2018. PMID: 28516874 Free article. Clinical Trial.
Secukinumab 150/300 mg Provides Sustained Improvements in the Signs and Symptoms of Active Ankylosing Spondylitis: 3-Year Results from the Phase 3 MEASURE 3 Study.
Pavelka K, Kivitz AJ, Dokoupilova E, Blanco R, Maradiaga M, Tahir H, Wang Y, Porter BO, Stefanska A, Richards HB, Rohrer S; MEASURE 3 study group. Pavelka K, et al. Among authors: porter bo. ACR Open Rheumatol. 2020 Feb;2(2):119-127. doi: 10.1002/acr2.11102. Epub 2020 Jan 20. ACR Open Rheumatol. 2020. PMID: 31957970 Free PMC article.
Improvement of Signs and Symptoms of Nonradiographic Axial Spondyloarthritis in Patients Treated With Secukinumab: Primary Results of a Randomized, Placebo-Controlled Phase III Study.
Deodhar A, Blanco R, Dokoupilová E, Hall S, Kameda H, Kivitz AJ, Poddubnyy D, van de Sande M, Wiksten AS, Porter BO, Richards HB, Haemmerle S, Braun J. Deodhar A, et al. Among authors: porter bo. Arthritis Rheumatol. 2021 Jan;73(1):110-120. doi: 10.1002/art.41477. Epub 2020 Nov 24. Arthritis Rheumatol. 2021. PMID: 32770640 Free PMC article. Clinical Trial.
Secukinumab and Sustained Improvement in Signs and Symptoms of Patients With Active Ankylosing Spondylitis Through Two Years: Results From a Phase III Study.
Marzo-Ortega H, Sieper J, Kivitz A, Blanco R, Cohen M, Martin R, Readie A, Richards HB, Porter B; Measure 2 Study Group. Marzo-Ortega H, et al. Among authors: porter b. Arthritis Care Res (Hoboken). 2017 Jul;69(7):1020-1029. doi: 10.1002/acr.23233. Epub 2017 Jun 7. Arthritis Care Res (Hoboken). 2017. PMID: 28235249 Free PMC article. Clinical Trial.
Long-term safety of secukinumab in patients with moderate-to-severe plaque psoriasis, psoriatic arthritis, and ankylosing spondylitis: integrated pooled clinical trial and post-marketing surveillance data.
Deodhar A, Mease PJ, McInnes IB, Baraliakos X, Reich K, Blauvelt A, Leonardi C, Porter B, Das Gupta A, Widmer A, Pricop L, Fox T. Deodhar A, et al. Among authors: porter b. Arthritis Res Ther. 2019 May 2;21(1):111. doi: 10.1186/s13075-019-1882-2. Arthritis Res Ther. 2019. PMID: 31046809 Free PMC article.
Secukinumab, an Interleukin-17A Inhibitor, in Ankylosing Spondylitis.
Baeten D, Sieper J, Braun J, Baraliakos X, Dougados M, Emery P, Deodhar A, Porter B, Martin R, Andersson M, Mpofu S, Richards HB; MEASURE 1 Study Group; MEASURE 2 Study Group. Baeten D, et al. Among authors: porter b. N Engl J Med. 2015 Dec 24;373(26):2534-48. doi: 10.1056/NEJMoa1505066. N Engl J Med. 2015. PMID: 26699169 Free article. Clinical Trial.
Secukinumab efficacy in anti-TNF-naive and anti-TNF-experienced subjects with active ankylosing spondylitis: results from the MEASURE 2 Study.
Sieper J, Deodhar A, Marzo-Ortega H, Aelion JA, Blanco R, Jui-Cheng T, Andersson M, Porter B, Richards HB; MEASURE 2 Study Group. Sieper J, et al. Among authors: porter b. Ann Rheum Dis. 2017 Mar;76(3):571-592. doi: 10.1136/annrheumdis-2016-210023. Epub 2016 Aug 31. Ann Rheum Dis. 2017. PMID: 27582421 Clinical Trial.
853 results